Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Taxes (2016 - 2025)

Historic Change in Taxes for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to -$21000.0.

  • Anika Therapeutics' Change in Taxes fell 10169.49% to -$21000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$372000.0, marking a year-over-year decrease of 13757.58%. This contributed to the annual value of $665000.0 for FY2024, which is 2547.17% up from last year.
  • Latest data reveals that Anika Therapeutics reported Change in Taxes of -$21000.0 as of Q3 2025, which was down 10169.49% from -$435000.0 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Change in Taxes ranged from a high of $1.3 million in Q2 2022 and a low of -$1.2 million during Q1 2021
  • Moreover, its 5-year median value for Change in Taxes was -$21000.0 (2025), whereas its average is $44842.1.
  • Per our database at Business Quant, Anika Therapeutics' Change in Taxes plummeted by 84819.28% in 2021 and then surged by 80000.0% in 2024.
  • Anika Therapeutics' Change in Taxes (Quarter) stood at -$888000.0 in 2021, then soared by 214.19% to $1.0 million in 2022, then tumbled by 58.38% to $422000.0 in 2023, then tumbled by 77.01% to $97000.0 in 2024, then tumbled by 121.65% to -$21000.0 in 2025.
  • Its Change in Taxes was -$21000.0 in Q3 2025, compared to -$435000.0 in Q2 2025 and -$13000.0 in Q1 2025.